These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1107 related articles for article (PubMed ID: 19833635)
1. In vitro activity of nemonoxacin (TG-873870), a novel non-fluorinated quinolone, against clinical isolates of Staphylococcus aureus, enterococci and Streptococcus pneumoniae with various resistance phenotypes in Taiwan. Chen YH; Liu CY; Lu JJ; King CH; Hsueh PR J Antimicrob Chemother; 2009 Dec; 64(6):1226-9. PubMed ID: 19833635 [TBL] [Abstract][Full Text] [Related]
2. Antimicrobial susceptibility of Gram-positive bacterial isolates from the Asia-Pacific region and an in vitro evaluation of the bactericidal activity of daptomycin, vancomycin, and teicoplanin: a SENTRY Program Report (2003-2004). Biedenbach DJ; Bell JM; Sader HS; Fritsche TR; Jones RN; Turnidge JD Int J Antimicrob Agents; 2007 Aug; 30(2):143-9. PubMed ID: 17531446 [TBL] [Abstract][Full Text] [Related]
3. [Surveillance on gram-positive bacteria isolated from patients with hospital acquired infections or community acquired infections]. Li JT; Li Y; Wang J; Zhonghua Yi Xue Za Zhi; 2003 Mar; 83(5):365-74. PubMed ID: 12820911 [TBL] [Abstract][Full Text] [Related]
4. In vitro effect of the presence of human albumin or human serum on the bactericidal activity of daptomycin against strains with the main resistance phenotypes in Gram-positives. Cafini F; Aguilar L; González N; Giménez MJ; Torrico M; Alou L; Sevillano D; Vallejo P; Prieto J J Antimicrob Chemother; 2007 Jun; 59(6):1185-9. PubMed ID: 17412725 [TBL] [Abstract][Full Text] [Related]
5. Global in vitro activity of tigecycline and linezolid against Gram-positive organisms collected between 2004 and 2009. Dowzicky MJ; Chmelařová E Int J Antimicrob Agents; 2011 Jun; 37(6):562-6. PubMed ID: 21497066 [TBL] [Abstract][Full Text] [Related]
6. Comparative bactericidal activities of daptomycin, glycopeptides, linezolid and tigecycline against blood isolates of Gram-positive bacteria in Taiwan. Huang YT; Liao CH; Teng LJ; Hsueh PR Clin Microbiol Infect; 2008 Feb; 14(2):124-9. PubMed ID: 18076671 [TBL] [Abstract][Full Text] [Related]
7. In vitro activity of tigecycline against quinolone-resistant Streptococcus pneumoniae, methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci. Garrison MW; Nuemiller JJ Int J Antimicrob Agents; 2007 Feb; 29(2):191-6. PubMed ID: 17174074 [TBL] [Abstract][Full Text] [Related]
8. Comparative in vitro activity of PGE 9262932 and fluoroquinolones against Canadian clinical Streptococcus pneumoniae isolates, including molecularly characterized ciprofloxacin-resistant isolates. Adam HJ; Schurek KN; Decorby MR; Weshnoweski B; Vashisht R; Karlowsky K; Hoban DJ; Zhanel GG J Antimicrob Chemother; 2006 Jul; 58(1):202-4. PubMed ID: 16636082 [TBL] [Abstract][Full Text] [Related]
10. Daptomycin antimicrobial activity tested against methicillin-resistant staphylococci and vancomycin-resistant enterococci isolated in European medical centers (2005). Sader HS; Watters AA; Fritsche TR; Jones RN BMC Infect Dis; 2007 Apr; 7():29. PubMed ID: 17442104 [TBL] [Abstract][Full Text] [Related]
11. Vancomycin MICs did not creep in Staphylococcus aureus isolates from 2002 to 2006 in a setting with low vancomycin usage. Alós JI; García-Cañas A; García-Hierro P; Rodríguez-Salvanés F J Antimicrob Chemother; 2008 Oct; 62(4):773-5. PubMed ID: 18552338 [TBL] [Abstract][Full Text] [Related]
12. Are fluoroquinolone-susceptible isolates of Streptococcus pneumoniae really susceptible? A comparison of resistance mechanisms in Canadian isolates from 1997 and 2003. Schurek KN; Adam HJ; Siemens CG; Hoban CJ; Hoban DJ; Zhanel GG J Antimicrob Chemother; 2005 Oct; 56(4):769-72. PubMed ID: 16126779 [TBL] [Abstract][Full Text] [Related]
13. In vitro antibacterial activity of beta-lactams and non-beta-lactams against Streptococcus pneumoniae isolates from Sydney, Australia. Gosbell IB; Fernandes LA; Fernandes CJ Pathology; 2006 Aug; 38(4):343-8. PubMed ID: 16916725 [TBL] [Abstract][Full Text] [Related]
14. In vitro activity of sitafloxacin against clinical strains of Streptococcus pneumoniae with defined amino acid substitutions in QRDRs of gyrase A and topoisomerase IV. Touyama M; Higa F; Nakasone C; Shinzato T; Akamine M; Haranaga S; Tateyama M; Nakasone I; Yamane N; Fujita J J Antimicrob Chemother; 2006 Dec; 58(6):1279-82. PubMed ID: 17056610 [TBL] [Abstract][Full Text] [Related]
15. In vitro prevention of the emergence of daptomycin resistance in Staphylococcus aureus and enterococci following combination with amoxicillin/clavulanic acid or ampicillin. Entenza JM; Giddey M; Vouillamoz J; Moreillon P Int J Antimicrob Agents; 2010 May; 35(5):451-6. PubMed ID: 20185277 [TBL] [Abstract][Full Text] [Related]
16. Investigation of the prevalence of patients co-colonized or infected with methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci in China: a hospital-based study. Wang Z; Cao B; Liu YM; Gu L; Wang C Chin Med J (Engl); 2009 Jun; 122(11):1283-8. PubMed ID: 19567138 [TBL] [Abstract][Full Text] [Related]
17. In vitro activity of ceftaroline (PPI-0903M, T-91825) against bacteria with defined resistance mechanisms and phenotypes. Mushtaq S; Warner M; Ge Y; Kaniga K; Livermore DM J Antimicrob Chemother; 2007 Aug; 60(2):300-11. PubMed ID: 17548456 [TBL] [Abstract][Full Text] [Related]
18. In vitro activity of telavancin against recent Gram-positive clinical isolates: results of the 2004-05 Prospective European Surveillance Initiative. Draghi DC; Benton BM; Krause KM; Thornsberry C; Pillar C; Sahm DF J Antimicrob Chemother; 2008 Jul; 62(1):116-21. PubMed ID: 18424792 [TBL] [Abstract][Full Text] [Related]
19. Evaluation of tedizolid against Staphylococcus aureus and enterococci with reduced susceptibility to vancomycin, daptomycin or linezolid. Barber KE; Smith JR; Raut A; Rybak MJ J Antimicrob Chemother; 2016 Jan; 71(1):152-5. PubMed ID: 26476277 [TBL] [Abstract][Full Text] [Related]
20. Emergence of high-level fluoroquinolone resistance in emm6 Streptococcus pyogenes and in vitro resistance selection with ciprofloxacin, levofloxacin and moxifloxacin. Malhotra-Kumar S; Van Heirstraeten L; Lammens C; Chapelle S; Goossens H J Antimicrob Chemother; 2009 May; 63(5):886-94. PubMed ID: 19279051 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]